5.30 0.00 (0.00%)
After hours: 5:07PM EDT
|Bid||5.23 x 2200|
|Ask||5.30 x 2200|
|Day's Range||5.18 - 5.35|
|52 Week Range||1.85 - 7.67|
|Beta (3Y Monthly)||2.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.33|
CORAL GABLES, Fla., Sept. 25, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.
Catalyst Pharmaceuticals, Inc. (CPRX) is commenting on today's trading activity in its common stock and on the current state of its capital resources. The Company is reporting that it is not aware of any information about the Company's activities that has not been reported that would give rise to today's decline in the market price of the Company's common stock. For the first six months of 2019, the Company reported net product revenue of $41.3 million and net income of $10.3 million (or $0.10 per basic and diluted share).
As the US$673m market cap Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released another year of negative earnings...
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
Catalyst Pharmaceuticals, Inc. (CPRX) today announced that it will not conclude the offering of shares of its common stock announced on Wednesday, September 11, 2019. The Company believes that the culmination of an offering at the current market price of the common stock is not in the best interest of the Company and its stockholders. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS), and spinal muscular atrophy (SMA) Type 3.
Catalyst Pharmaceuticals, Inc. (CPRX) announced today that it has commenced an underwritten public offering of 8.0 million shares of its common stock. Catalyst also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares in the offering are being sold by Catalyst.
CORAL GABLES, Fla., Aug. 28, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...
Catalyst (CPRX) delivered earnings and revenue surprises of 233.33% and 50.18%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Firdapse® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly.
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its support of Spinal Muscular Atrophy (SMA) Awareness Month. Taking place in August, SMA Awareness Month involves activities worldwide to spotlight the work the SMA community does year-round to raise awareness of the debilitating and potentially deadly disease. “We are proud to be part of the global movement to raise awareness of SMA and recognize the importance of developing new evidence-based medicines required to improve the lives of patients, families and caregivers afflicted with SMA,” said Patrick J. McEnany, Chairman and CEO of Catalyst.